CDKN2A A20P

CI-VAR-00000081Explore in graph →NP_000068.1:p.Ala20ProNM_000077.4:c.58G>CClinVar 576362 CIViC 1522 rs760065045

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Melanoma1
CDKN2A A20P	Palbociclib	Predictive	D	Supports Sensitivity Response	—	submitted	EID4524 In an in vitro study, a melanoma C052 cell line expressing CDKN2A A20P mutation (endogenous) demonstrated sensitivity to palbociclib treatment (GI50: 79nM). Sensitivity was determined by assessing cel… (full text at CIViC) PMID 24495407 · Young et al., 2014 · Open in CIViC	civic
Unmapped disease1unmapped disease
CDKN2A A20P	(functional)	Functional	D	Supports Loss Of Function	3	submitted	EID9323 Analysis of several CDKN2A variants was performed to discover their functional impact. Both in vitro and in vivo binding assays showed that the A20P mutation resulted in complete loss of binding to CD… (full text at CIViC) PMID 10498896 ·

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
576362	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications	1	Familial melanoma; Hereditary cancer-predisposing syndrome; Melanoma-pancreatic cancer syndrome	germline	3	Aug 14, 2025	clinvar